Pharmaceuticals
NanoViricides Advances Measles Drug Development with Promising Broad-Spectrum Antiviral
NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate targeting measles amid declining vaccination rates. The drug shows potential for addressing infectious disease challenges with its unique therapeutic approach.
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700
Tonix Pharmaceuticals presented positive preclinical results for TNX-1700, a fusion protein showing potential in reducing immunosuppressive cells and enhancing anti-tumor immune responses in gastric cancer models, particularly when combined with anti-PD1 therapy.
AHA Awards $1M to Study Cardiovascular Benefits of GLP-1 Medications Across Diverse Populations
The American Heart Association is funding seven research projects to investigate how GLP-1 medications impact cardiovascular health in different patient groups, with the goal of identifying who benefits most from these treatments and understanding variations in therapeutic response.
Calidi Biotherapeutics Names New CEO, Grants Significant Stock Option Package
Calidi Biotherapeutics has appointed Eric Poma as its new CEO and granted him a substantial stock option package, signaling potential strategic shifts in the clinical-stage biotechnology company's leadership and future direction.
Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.
Helix BioPharma Strengthens Leadership with Strategic Executive Appointments
Helix BioPharma has appointed Veronika Kandziora as Chief Operating Officer and Dr. Jessica Kourniaktis as Director of Communications, signaling a strategic move to accelerate growth and enhance communication in its mission to develop innovative cancer treatments.
NeuroSense's ALS Drug PrimeC Shows Promise with 58% Survival Improvement, Pharmaceutical Partnership Imminent
NeuroSense Therapeutics' experimental ALS treatment PrimeC demonstrates significant potential in clinical trials, with the company positioned for a major pharmaceutical partnership and potential breakthrough in neurodegenerative disease treatment.
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.
Zelenirstat Shows Promise in Disrupting Triple-Negative Breast Cancer Cell Growth
Pacylex Pharmaceuticals' lead drug zelenirstat demonstrates potential to disrupt mitochondrial function in triple-negative breast cancer cells, potentially offering new insights into cancer treatment strategies.
Silexion Therapeutics Partners with Catalent to Advance Breakthrough KRAS Cancer Treatment
Silexion Therapeutics is collaborating with Catalent to develop SIL204, an innovative RNA interference therapy targeting multiple KRAS mutations in pancreatic cancer, with potential to transform treatment paradigms in a $470 billion precision medicine market.
GeoVax Set to Disclose Q1 2025 Financial Results and Provide Corporate Update
Clinical-stage biotechnology company GeoVax Labs will release its first quarter 2025 financial results and host a conference call, offering insights into its COVID-19 vaccine development and oncology programs. The announcement provides stakeholders an opportunity to learn about the company's recent progress and strategic direction.
Nutriband Strengthens Intellectual Property for Abuse-Deterrent Drug Delivery Technology
Nutriband secures new U.S. trademark and international patents for its AVERSA™ transdermal drug delivery platform, positioning the company to target a significant market opportunity in abuse-deterrent pharmaceuticals.
Quantum BioPharma Announces Corporate Updates and Debt Settlement Strategy
Quantum BioPharma Ltd. has granted restricted share units and approved debt settlement through share issuance, signaling strategic financial maneuvering and potential investment opportunities in the biotech sector.
Creative Biolabs Advances Drug Delivery with Custom Emulsion Technology
Creative Biolabs has developed innovative emulsion formulations designed to enhance drug stability and bioavailability, offering customized solutions for challenging pharmaceutical delivery systems. The breakthrough technology addresses critical drug solubility issues across various pharmaceutical applications.
Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
Nutriband's CEO Gareth Sheridan has been recognized as a finalist in the EY Entrepreneur of the Year Awards, highlighting the company's innovative work in transdermal drug delivery and abuse-deterrent technologies.
Indian Generic Cancer Drug Offers 98% Cost Reduction Compared to US Brand Name
A critical development in cancer treatment accessibility shows Indian-manufactured generic Ibrutinib (Ibrunat) is available for as little as $250 per month, compared to $15,000 for the US brand-name Imbruvica, while offering the same therapeutic benefits for blood cancer patients.
Major Healthcare Partnership Aims to Revolutionize Oral Thrush Treatment
A new three-way partnership between Shear Kershman Labs, Texas A&M College of Dentistry, and Innovative MedTech Inc. promises to transform oral healthcare through an innovative drug delivery system that could benefit millions of patients suffering from oral thrush.
Pacylex Advances Cancer Treatment Innovation with NMT Inhibitor Technology
Pacylex Pharmaceuticals is advancing its novel cancer treatment technology through major industry conferences, showcasing both oral and antibody-drug conjugate applications of their N-myristoyltransferase inhibitors, marking a significant development in targeted cancer therapy.